CD8A and neoplasm: This team then developed an immune scoring system based on the distribution of CD3+ and CD8+ TILs in the tumor and invasive edge in the following year, which could serve as a prognostic factor for the patient’s local recurrence-free survival (LRFS) and OS (85).